{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:21:29Z","timestamp":1789176089069,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejps.2023.106399","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T20:50:21Z","timestamp":1675457421000},"page":"106399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation"],"prefix":"10.1016","volume":"183","author":[{"given":"Alejandra","family":"Schiavo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Fagiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki F.","family":"Troc\u00f3niz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-6367","authenticated-orcid":false,"given":"Manuel","family":"Ibarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106399_bib0001","series-title":"Valproate","first-page":"47","article-title":"Chemistry and biotransformation","author":"Abbott","year":"1999"},{"issue":"9\u201310","key":"10.1016\/j.ejps.2023.106399_bib0002","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s002280000211","article-title":"Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers","volume":"56","author":"Addison","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106399_bib0003","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: Inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA","volume":"55","author":"Aires","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejps.2023.106399_bib0004","series-title":"StatPearls [Internet]","article-title":"Hyperammonemia","author":"Ali","year":"2022"},{"issue":"2","key":"10.1016\/j.ejps.2023.106399_bib0005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jchromb.2005.11.028","article-title":"Development and validation of a sensitive assay of valproic acid in human plasma by high-performance liquid chromatography without prior derivatization","volume":"830","author":"Amini","year":"2006","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.ejps.2023.106399_bib0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00467-011-1838-5","article-title":"Hyperammonemia in review: Pathophysiology, diagnosis, and treatment","volume":"27","author":"Auron","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106399_bib0007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.9740\/mhc.2018.03.073","article-title":"Valproic acid\u2013induced hyperammonemia: Incidence, clinical significance, and treatment management","volume":"8","author":"Baddour","year":"2018","journal-title":"Ment. Heal. Clin."},{"key":"10.1016\/j.ejps.2023.106399_bib0008","unstructured":"Bertrand Iooss, A., Da Veiga, S., Janon, A., Pujol, G., contribu-tions from Baptiste Broto, with, Boumhaout, K., Delage, T., El Amri, R., Fruth, J., Gilquin, L., Guillaume, J., Il Idrissi, M., Le Gratiet, L., Lemaitre, P., Marrel, A., Meynaoui, A., Nelson, B. L., \u2026 Weber, F. 2021. Package \u201csensitivity\u201d Title Global Sensitivity Analysis of Model Outputs."},{"key":"10.1016\/j.ejps.2023.106399_bib0009","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S1665-2681(19)31609-6","article-title":"Determination of ammonia concentrations in cirrhosis patients-still confusing after all these years?","volume":"10","author":"Blanco Vela","year":"2011","journal-title":"Ann. Hepatol."},{"issue":"10","key":"10.1016\/j.ejps.2023.106399_bib0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1212\/WNL.56.10.1405","article-title":"Effect of L-carnitine treatment for valproate-induced hepatotoxicity","volume":"56","author":"Bohan","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejps.2023.106399_bib0011","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.25011\/cim.v32i1.5082","article-title":"Comparison of pharmacokinetics of L-carnitine, Acetyl- L-carnitine and Propionyl-Lcarnitine after single oral administration of L-carnitine in healthy volunteers","volume":"32","author":"Cao","year":"2009","journal-title":"Clin. Investig. Med."},{"key":"10.1016\/j.ejps.2023.106399_bib0012","first-page":"1","article-title":"Current practices for QSP model assessment: an IQ consortium survey","volume":"11","author":"Chan","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2023.106399_bib0013","first-page":"1","article-title":"Study of Valproic Acid-Enhanced Hepatocyte Steatosis","author":"Chang","year":"2016","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ejps.2023.106399_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/479364","article-title":"Molecular and Therapeutic Potential and Toxicity of Valproic Acid","author":"Chateauvieux","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.ejps.2023.106399_bib0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yebeh.2007.06.015","article-title":"The measurement of ammonia blood levels in patients taking valproic acid: Looking for problems where they do not exist?","volume":"11","author":"Chicharro","year":"2007","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.ejps.2023.106399_bib0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.yebeh.2007.12.007","article-title":"The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?","volume":"12","author":"Chicharro","year":"2008","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.ejps.2023.106399_bib0017","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.genhosppsych.2011.12.009","article-title":"Valproate-induced hyperammonemic encephalopathy: An update on risk factors, clinical correlates and management","volume":"34","author":"Chopra","year":"2012","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.ejps.2023.106399_bib0018","unstructured":"Ciprian \u0162incu, R. 2017. FAVOURABLE RESULTS FOR L-CARNITINE USE IN VALPROIC ACID ACUTE POISONING. Farmacia (Vol. 65)."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2023.106399_bib0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","article-title":"Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy","volume":"53","author":"Cloyd","year":"2003","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.ejps.2023.106399_bib0020","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1471-4159.1994.62031137.x","article-title":"Valproate Increases Glutaminase and Decreases Glutamine Synthetase Activities in Primary Cultures of Rat Brain Astrocytes","volume":"62","author":"Collins","year":"1994","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.ejps.2023.106399_bib0021","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1525-1594.1996.tb04544.x","article-title":"Determinants of ammonia clearance by hemodialysis","volume":"20","author":"Cordoba","year":"1996","journal-title":"Artif. Organs"},{"key":"10.1016\/j.ejps.2023.106399_bib0022","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00007691-198612000-00005","article-title":"Variable Free and Total Valproic Acid Concentrations in Sole- and Multi-Drug Therapy","volume":"8","author":"Cramer","year":"1986","journal-title":"Ther. Drug Monit."},{"issue":"14","key":"10.1016\/j.ejps.2023.106399_bib0023","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2174\/1381612828666220422091159","article-title":"Tissue Drug Concentration","volume":"28","author":"Fagiolino","year":"2022","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.ejps.2023.106399_bib0024","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1586\/17512433.2014.871202","article-title":"Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity","volume":"7","author":"Felker","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106399_bib0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.9.2.285","article-title":"Oral valproic acid for epilepsy - Long-term experience in therapy and side effects","volume":"9","author":"Gerstner","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejps.2023.106399_bib0026","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: Pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"issue":"3","key":"10.1016\/j.ejps.2023.106399_bib0027","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1097\/MJT.0000000000000706","article-title":"Levocarnitine for the Treatment of Valproic Acid\u2013Induced Hyperammonemic Encephalopathy in Children: The Experience of a Large, Tertiary Care Pediatric Hospital and a Poison Center","volume":"26","author":"Glatstein","year":"2019","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.ejps.2023.106399_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113860","article-title":"Valproic acid affects fatty acid and triglyceride metabolism in HepaRG cells exposed to fatty acids by different mechanisms","volume":"177","author":"Gr\u00fcnig","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2023.106399_bib0029","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/17425250902911455","article-title":"A review of valproate in psychiatric practice","volume":"5","author":"Haddad","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"5","key":"10.1016\/j.ejps.2023.106399_bib0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00558253","article-title":"Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects","volume":"35","author":"Harper","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106399_bib0031","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","article-title":"Allometric size: The scientific theory and extension to normal fat mass","volume":"109","author":"Holford","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2023.106399_bib0032","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0272-6386(03)00112-4","article-title":"The role of carnitine in normal and altered fatty acid metabolism","volume":"41","author":"Hoppel","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejps.2023.106399_bib0033","series-title":"Clin. Methods Hist. Phys. Lab. Exam.","article-title":"BUN and Creatinine","author":"Hosten","year":"1990"},{"issue":"5","key":"10.1016\/j.ejps.2023.106399_bib0034","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3476(05)80306-3","article-title":"Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children","volume":"119","author":"Hug","year":"1991","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.ejps.2023.106399_bib0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","article-title":"Sex related differences on valproic acid pharmacokinetics after oral single dose","volume":"40","author":"Ibarra","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"3","key":"10.1016\/j.ejps.2023.106399_bib0036","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1034\/j.1600-0773.2002.900304.x","article-title":"Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients","volume":"90","author":"Kondo","year":"2002","journal-title":"Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.ejps.2023.106399_bib0037","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/cc3742","article-title":"Science review: Carnitine in the treatment of valproic acid-induced toxicity - What is the evidence?","volume":"9","author":"Lheureux","year":"2005","journal-title":"Crit. Care."},{"key":"10.1016\/j.ejps.2023.106399_bib0038","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2920108","article-title":"Carnitine and\/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia","author":"Maldonado","year":"2016","journal-title":"Biomed Res. Int.2920108."},{"issue":"3","key":"10.1016\/j.ejps.2023.106399_bib0039","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0300060517703278","article-title":"L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report","volume":"45","author":"Maldonado","year":"2017","journal-title":"J. Int. Med. Res."},{"issue":"7","key":"10.1016\/j.ejps.2023.106399_bib0040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/15563650802178136","article-title":"Valproic acid poisoning: An evidence-based consensus guideline for out-of-hospital management","volume":"46","author":"Manoguerra","year":"2008","journal-title":"Clin. Toxicol."},{"issue":"9566","key":"10.1016\/j.ejps.2023.106399_bib0041","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"8\u20139","key":"10.1016\/j.ejps.2023.106399_bib0042","first-page":"18","article-title":"The Effect of Carnitine Supplementation on Hyperammonemia and Carnitine Deficiency Treated with Valproic Acid in a Psychiatric Setting","volume":"12","author":"Nakamura","year":"2015","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.ejps.2023.106399_bib0043","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.seizure.2018.04.012","article-title":"Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy","volume":"59","author":"Nasreddine","year":"2018","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.ejps.2023.106399_bib0044","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13613-022-00984-z","article-title":"L-carnitine does not improve valproic acid poisoning management: a cohort study with toxicokinetics and concentration\/effect relationships","volume":"12","author":"Nguyen","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.ejps.2023.106399_bib0045","doi-asserted-by":"crossref","unstructured":"Nitsche, V., Mascher, H. 1982. The Pharmacokinetics of Valproic Acid After Oral and Parenteral Administration in Healthy Volunteers, 23, 153\u2013162.","DOI":"10.1111\/j.1528-1157.1982.tb05063.x"},{"key":"10.1016\/j.ejps.2023.106399_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108220","article-title":"Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate","volume":"122","author":"Okumura","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"7\u20138","key":"10.1016\/j.ejps.2023.106399_bib0047","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1345\/aph.1P135","article-title":"L-Carnitine for Acute Valproic Acid Overdose: A Systematic Review of Published Cases","volume":"44","author":"Perrott","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejps.2023.106399_bib0048","series-title":"StatPearls [Internet]","article-title":"Valproic Acid","author":"Rahman","year":"2022"},{"key":"10.1016\/j.ejps.2023.106399_bib0049","unstructured":"Rohatgi, A. 2022, September. WebPlotDigitizer. Pacifica, California, USA."},{"key":"10.1016\/j.ejps.2023.106399_bib0050","article-title":"A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid","author":"Safdar","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejps.2023.106399_bib0051","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejps.2023.106399_bib0052","unstructured":"Swihart, B., Lindsey, J. 2019. gnlm: Generalized Nonlinear Regression Models R package."},{"issue":"6","key":"10.1016\/j.ejps.2023.106399_bib0053","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1081\/CLT-120014645","article-title":"Valproic Acid Toxicity: Overview and Management","volume":"40","author":"Sztajnkrycer","year":"2002","journal-title":"J. Toxicol. Clin. Toxicol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106399_bib0054","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(15)00398-1","article-title":"The remarkable story of valproic acid","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejps.2023.106399_bib0055","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/217269","article-title":"Hyperammonemia associated with valproic acid concentrations","author":"V\u00e1zquez","year":"2014","journal-title":"Biomed Res. Int."},{"issue":"5","key":"10.1016\/j.ejps.2023.106399_bib0056","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3122\/jabfm.2007.05.070062","article-title":"Valproate-associated Hyperammonemic Encephalopathy","volume":"20","author":"Wadzinski","year":"2007","journal-title":"J. Am. Board Fam. Med."},{"key":"10.1016\/j.ejps.2023.106399_bib0057","series-title":"ggplot2: Create Elegant Data Visualisations Using the Grammar of Graphics","author":"Wickham","year":"2016"},{"key":"10.1016\/j.ejps.2023.106399_bib0058","unstructured":"Wickham, H., Fran\u00e7ois, R., Henry, L., M\u00fcller, K. 2018. dplyr: A Grammar of Data Manipulation. R package version."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:07:23Z","timestamp":1760530043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":58,"alternative-id":["S0928098723000301"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106399","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106399"}}